Atlas Genetics

atlasgenetics.com

Atlas Genetics is creating a new category of in vitro diagnostics focused on decentralized, near-­patient and Point-­of-­Care (POC) testing for everyone. With routine testing rapidly moving from the “hub” to the “spokes,” Atlas’s io® platform is poised to benefit from this growing trend in decentralized testing. The company’s proprietary technology platform positions Atlas in the vanguard of the rapidly evolving and increasingly patient-directed landscape of consumer diagnostics, where convenience, rapid “test and treat,” and portability of platform are becoming critical to success. Atlas aims to meet patients where they are and improve patient outcomes by arming healthcare professionals with a simple-­to-­use, rapid and cost-­effective solution for on-­demand diagnosis of infectious diseases. A sample-answer time of 30 mins, high accuracy and low cost are hallmarks of the company’s broad platform for a broad range of infectious diseases.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact, Medical

CARIS LIFE SCIENCES AND FLARE THERAPEUTICS ANNOUNCE STRATEGIC PREFERRED PORTFOLIO PARTNERSHIP TO ADVANCE FLARE'S PRECISION ONCOLOGY PIPELINE

prnewswire | April 17, 2023

news image

Caris Life Sciences® the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, and Flare Therapeutics, a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced a multi-year strategic collaboration to accelerate precision medicine approaches across five of Flare's therapeutic programs into clinical trials through advanced molec...

Read More

BIOLOGICAL DYNAMICS EXPANDS BIOMARKERS RESEARCH TO DEVELOP ASSAYS FOR DETECTION AND QUANTIFICATION OF BLOOD-BASED BIOMARKERS

Biological Dynamics | July 30, 2020

news image

Biological Dynamics, Inc., an innovative diagnostic company committed to improving global health, announces a new biomarkers program designed for drug development applications in Alzheimer's Disease (AD). The company will use its proprietary Verita™ platform to develop a portfolio of assays for detection and quantification of blood-based biomarkers associated with AD and other neurodegenerative conditions. The program is funded by the Alzheimer's Drug Discovery Foundation's (AD...

Read More

AFTER BAGGING $200M-PLUS IN 2019, PASSAGE BIO GUNS FOR $125M IPO

FierceBiotech | February 04, 2020

news image

Despite pulling off two megarounds in 2019, Passage Bio is returning to the funding well—but this time, it’s going public. The company filed for a $125 million IPO, which will bankroll the development of its three lead gene therapy programs in dementia, Krabbe disease and rare childhood disease GM1 gangliosidosis. Those programs were among five that Passage picked up in its partnership with the University of Pennsylvania’s Gene Therapy Program in February 2019. At the sam...

Read More

Industrial Impact

ADCENTRX AND AVANTGEN ENTER A NEW PARTNERSHIP WITH A THREE-YEAR, MULTI-TARGET COLLABORATION TO DISCOVER ANTIBODIES FOR NOVEL ANTIBODY-DRUG CONJUGATES

Adcentrx Therapeutics | February 15, 2022

news image

Adcentrx Therapeutics a biotechnology company focused on accelerating breakthroughs in antibody drug conjugate ("ADC") therapeutic development, and AvantGen, a leader in the use of yeast display technology for human antibody discovery and optimization, announced today a three-year, multi-target partnership for the discovery of antibodies to be developed into novel ADC therapeutic candidates. Under the terms of the collaboration, Adcentrx will specify targets against whic...

Read More
news image

Industrial Impact, Medical

CARIS LIFE SCIENCES AND FLARE THERAPEUTICS ANNOUNCE STRATEGIC PREFERRED PORTFOLIO PARTNERSHIP TO ADVANCE FLARE'S PRECISION ONCOLOGY PIPELINE

prnewswire | April 17, 2023

Caris Life Sciences® the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, and Flare Therapeutics, a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced a multi-year strategic collaboration to accelerate precision medicine approaches across five of Flare's therapeutic programs into clinical trials through advanced molec...

Read More
news image

BIOLOGICAL DYNAMICS EXPANDS BIOMARKERS RESEARCH TO DEVELOP ASSAYS FOR DETECTION AND QUANTIFICATION OF BLOOD-BASED BIOMARKERS

Biological Dynamics | July 30, 2020

Biological Dynamics, Inc., an innovative diagnostic company committed to improving global health, announces a new biomarkers program designed for drug development applications in Alzheimer's Disease (AD). The company will use its proprietary Verita™ platform to develop a portfolio of assays for detection and quantification of blood-based biomarkers associated with AD and other neurodegenerative conditions. The program is funded by the Alzheimer's Drug Discovery Foundation's (AD...

Read More
news image

AFTER BAGGING $200M-PLUS IN 2019, PASSAGE BIO GUNS FOR $125M IPO

FierceBiotech | February 04, 2020

Despite pulling off two megarounds in 2019, Passage Bio is returning to the funding well—but this time, it’s going public. The company filed for a $125 million IPO, which will bankroll the development of its three lead gene therapy programs in dementia, Krabbe disease and rare childhood disease GM1 gangliosidosis. Those programs were among five that Passage picked up in its partnership with the University of Pennsylvania’s Gene Therapy Program in February 2019. At the sam...

Read More
news image

Industrial Impact

ADCENTRX AND AVANTGEN ENTER A NEW PARTNERSHIP WITH A THREE-YEAR, MULTI-TARGET COLLABORATION TO DISCOVER ANTIBODIES FOR NOVEL ANTIBODY-DRUG CONJUGATES

Adcentrx Therapeutics | February 15, 2022

Adcentrx Therapeutics a biotechnology company focused on accelerating breakthroughs in antibody drug conjugate ("ADC") therapeutic development, and AvantGen, a leader in the use of yeast display technology for human antibody discovery and optimization, announced today a three-year, multi-target partnership for the discovery of antibodies to be developed into novel ADC therapeutic candidates. Under the terms of the collaboration, Adcentrx will specify targets against whic...

Read More